DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty

Information source: Baxter Healthcare Corporation
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Seroma; Hematoma

Intervention: FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma) (Procedure); Standard of care (Procedure)

Phase: Phase 2

Status: Recruiting

Sponsored by: Baxter Healthcare Corporation

Official(s) and/or principal investigator(s):
Steve Z Abrams, MD, MBA, Study Director, Affiliation: Baxter Healthcare Corporation

Summary

The purpose of the study is to compare the safety and efficacy of ARTISS versus standard of care in adhering tissue places and reducing seroma/hematoma formation in subjects undergoing abdominoplasty.

Clinical Details

Official title: A Randomized, Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of ARTISS (FS VH S/D 4 S-apr) for Flap Adherence in Subjects Undergoing Abdominoplasty

Study design: Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Effect of ARTISS on the improvement of flap adherence in subjects undergoing abdominoplasty, as indicated by a reduction in drainage volume

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subject is 18 to 75 years of age at the time of screening

- Subject is planned for primary standard abdominoplasty (status post Cesarean section

or liposuction performed more than 6 months prior to enrollment in the study are allowed)

- If the subject is of childbearing potential; presents with a negative pregnancy test,

and agrees to employ adequate birth control measures for the duration of the study

- Subject resides within 100 miles of the investigational site and is willing and able

to comply with the scheduling requirements of the protocol (notably home visits by study personnel)

- Subject is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

- Subject is obese (body mass index [BMI] > 30 before surgery)

- Subject has experienced massive weight loss (subject has a history of obesity during

adult life; subject lost more than 20 BMI unit score, subject has undergone a bariatric surgery)

- Subject has a history of active smoking within the previous 12 months

- Subject is elected for a non-standard abdominoplasty (extended, limited or

mini-abdominoplasty, endoscopic, fleur-de-lis or circumferential abdominoplasty) or panniculectomy

- Subject has scars on the abdominal wall above the umbilicus. Vertical midline,

laparoscopic punctures, or liposuction punctures are permitted

- Subject is planned for other "body lifting" procedures (eg to the arms, legs, back

etc.)

- Subject is planned for combined abdominoplasty with other cosmetic procedures

including liposuction (restricted liposuction of the waist line and the lower back is allowed, as long as the integrity of the surgical spaces is maintained)

- Subject has an active or chronic skin disorder, history or evidence of keloid

formation, or hypertrophic scarring

- Subject has a history of gastrointestinal disorders (eg Irritable Bowel Syndrome)

requiring prescription medications

- Subject has a known abdominal hernia that requires mesh fixation

- Subject has a documented hiatal hernia or acid reflux disease

- Subjects with congenital or acquired immunodeficiency disorders

- Subject has uncontrolled diabetes mellitus (HbA1c > 7. 0)

- Subject has a history of cardio-vascular disease including uncontrolled hypertension

(> 140/90 mm Hg)

- Subject has a clinically diagnosed psychiatric disorder (including obsessive

compulsive disorders)

- Subject has a known (documented) bleeding or coagulation disorder including history

of thromboembolic events

- Subject is being treated with anti-coagulants or with Aspirin (that was not

discontinued 7 days prior to surgery)

- Subject is receiving active treatment for a malignancy

- Subject has a connective tissue disorder

- Subject has received chronic treatment with immunosuppressive drugs, systemic

corticosteroids, or other chronic treatments within 30 days prior to the surgery

- Subject has participated in another clinical study involving an investigational

product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study

- Subject has a known sensitivity to fibrin sealants

- Subject is a friend, employee, or relative of the investigator or other study

personnel

Locations and Contacts

Mei Li Surgery Center, Beverly Hills, California 90210, United States; Recruiting
Linda Li, MD, Phone: 310-273-6252, Email: admin@lindalimd.com
Linda Li, MD, Principal Investigator

Center for Plastic Surgery and Skin Care, Fort Lauderdale, Florida 33308, United States; Not yet recruiting
Jorge Perez, MD, Phone: 954-351-2200, Email: Jalexp3@aol.com
Jorge Perez, MD, Principal Investigator

Miami Plastic Surgery, Miami, Florida 33176, United States; Recruiting
Michael Kelly, MD, Phone: 305-595-2969, Email: mkelly@miamiplasticsurgery.com
Michael Kelly, MD, Principal Investigator

Places Plastic Surgery, Atlanta, Georgia 30327, United States; Recruiting
T. Roderick Hester, MD, Phone: 404-351-0051, Email: oleblueeyes@mindspring.com
T. Roderick Hester, MD, Principal Investigator

The Practice of Gary Wiesman, M.D. and Irvin Wiesman, M.D. and Associates, Chicago, Illinois 60654, United States; Recruiting
Irvin Wiesman, MD, Phone: 312-981-1290, Email: iwiesman@sbcglobal.net
Irvin Wiesman, MD, Principal Investigator

UT Southwestern Medical Center, Department of Plastic Surgery, Dallas, Texas 75390-9132, United States; Recruiting
Rodney J Rohrich, MD, Phone: 214-645-3119, Email: rod.rohrich@UTsouthwestern.edu
Rodney J Rohrich, MD, Principal Investigator

Additional Information

Starting date: May 2010
Last updated: June 28, 2010

Page last updated: October 04, 2010

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012